Novel Structural Insights of Glutamate Racemase from Mycobacterium tuberculosis through Modeling and Docking Studies
Authors: Jayashree Ramana
An alarming emergence of multidrug-resistant strains of the tuberculosis pathogen Mycobacterium tuberculosis and continuing high worldwide incidence of tuberculosis has invigorated the search for novel drug targets. The enzyme glutamate racemase (MurI) in bacteria catalyzes the stereoconversion of L-glutamate to D-glutamate which is a component of the peptidoglycan cell wall of the bacterium. The inhibitors targeted against MurI from several bacterial species have been patented and are advocated as promising antibacterial agents. However there are none available against MurI from Mycobacterium tuberculosis, due to the lack of its threedimensional structure. This work accomplished two major objectives. First, the tertiary structure of MtMurI was deduced computationally through homology modeling using the templates from bacterial homologues. It is speculated that like in other Gram-positive bacteria, MtMurI exists as a dimer and many of the protein interactions at the dimer interface are also conserved. Second, potent candidate inhibitors against MtMurI were identified through docking against already known inhibitors in other organisms.
Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1087382Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 2505
 Zumla A, Nahid P, Cole ST: Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
 Garret RH, Grisham CM: Membranes and Cell Surfaces. In Biochemistry. 2nd edition; 1999: 279-281.
 Silver LL: Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? Biochemical Pharmacology 2006, 71:996- 1005.
 de Jonge BLM, Kutschke A, Uria-Nickelsen M, Kamp HD, Mills SD: Pyrazolopyrimidinediones Are Selective Agents for Helicobacter pylori That Suppress Growth through Inhibition of Glutamate Racemase (MurI). Antimicrobial Agents and hemotherapy 2009, 53:3331-3336.
 de Dios A, Prieto L, MartÃ-n JA, Rubio A, Ezquerra J, Tebbe M, LÃ³pez de Uralde B, MartÃ-n J, SÃ¡nchez A, LeTourneau DL, et al: 4- Substituted d-Glutamic Acid Analogues:â€‰ The First Potent Inhibitors of Glutamate Racemase (MurI) Enzyme with Antibacterial Activity. Journal of Medicinal Chemistry 2002, 45:4559-4570.
 Sengupta S, Ghosh S, Nagaraja V: Moonlighting function of glutamate racemase from Mycobacterium tuberculosis: racemization and DNA gyrase inhibition are two independent activities of the enzyme. Microbiology 2008, 154:2796-2803.
 Sengupta S, Shah M, Nagaraja V: Glutamate racemase from Mycobacterium tuberculosis inhibits DNA gyrase by affecting its DNAbinding. Nucleic Acids Research 2006, 34:5567-5576.
 Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al: Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
 Altschul S. F, Madden T. L, Schäffer A. A, Zhang J, Zhang Z, Miller W, Lipman D. J: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997, 25:3389- 3402.
 Sali A, Blundell T. L: Comparative Protein Modelling by Satisfaction of Spatial Restraints. Journal of Molecular Biology 1993, 234:779-815.
 Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM: AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 1996, 8:477-486.
 Negi SS, Schein CH, Oezguen N, Power TD, Braun W: InterProSurf: a web server for predicting interacting sites on protein surfaces. Bioinformatics 2007, 23:3397-3399.
 Wallace AC, Laskowski RA, Thornton JM: LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995, 8:127-134.